ResMed Inc. is a global leader in digital health and cloud-connected medical devices. The company designs innovative solutions to treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Their digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases. ResMed's comprehensive out-of-hospital (OOH) software platforms support professionals and caregivers, helping people stay healthy in their homes or care settings. The company's core business model is centered around providing connected care solutions that improve patient outcomes and reduce healthcare costs.

• Employees: 9,980+
• Geographic Footprint: 140+ countries
• Headquarters: San Diego, CA
• Founded: 1989
• Revenue: $4.685 billion (FY2024)
• Key Subsidiaries/Brands: ResMed, Brightree, HEALTHCAREfirst, MatrixCare, MEDIFOX DAN

• CEO: Michael J. Farrell
• CFO: Brett A. Sandercock
• Board Chair: Peter C. Farrell

Michael J. Farrell is also the Chairman of the Board. Peter C. Farrell is the Chair Emeritus.

• Annual Revenue: $4.685 billion (FY2024)
• Net Income: $1.021 billion
• Total Assets: $6.872 billion
• Employees: 9,980+
• Key Financial Highlights: Revenue increased by 11% compared to FY2023. Gross profit increased by 13%. Net income increased by 14%.

ResMed's main product categories and services include:

• Devices: Cloud-connected CPAP, APAP, bilevel, adaptive servo-ventilation (ASV), and high flow therapy (HFT) devices.
• Diagnostic Products: Sleep recorders for clinics, hospitals, and home use, such as ApneaLink Air and NightOwl.
• Mask Systems: A variety of nasal, nasal pillows, and full-face masks.
• Connected Solutions: Cloud-based patient management and engagement platforms like AirView, myAir, and U-Sleep.
• SaaS Products: Software solutions for HME providers and long-term care providers, including Brightree, HEALTHCAREfirst, MatrixCare, and MEDIFOX DAN.

ResMed operates through two main segments:

• Sleep and Respiratory Care: Focuses on devices, diagnostic products, and mask systems for sleep apnea and other respiratory conditions.
• Software as a Service (SaaS): Provides software platforms for out-of-hospital care settings.

In FY2024, Sleep and Respiratory Care contributed $4.101 billion in revenue, while SaaS contributed $584.1 million.

ResMed's strategy focuses on:

• Continuous product development and innovation in sleep apnea and respiratory care products.
• Broadening their digital health technology foundation.
• Expanding SaaS solutions in out-of-hospital care settings.
• Expanding geographic presence.
• Increasing public and clinical awareness of sleep apnea and related conditions.
• Expanding into new clinical applications.
• Leveraging the experience of their management team.

ResMed primarily operates in the sleep and respiratory care market, which is characterized by:

• Primary Industry: Medical devices and healthcare software.
• Market Trends: Increasing awareness of sleep apnea, growing adoption of digital health solutions, and a shift towards out-of-hospital care.
• Major Competitors: Philips, Fisher & Paykel Healthcare, DeVilbiss Healthcare, Apex Medical Corporation, BMC Medical Co. Ltd., React Health Corporation, and Lowenstein.

• Market Risks: Intense competition, healthcare payment reforms, and changing consumer preferences.
• Operational Risks: Supply chain disruptions, manufacturing constraints, and dependence on IT systems.
• Financial Risks: Fluctuations in foreign currency exchange rates and the impact of global macroeconomic conditions.
• Regulatory Risks: Compliance with FDA and other regulatory requirements, and changes in healthcare laws.
• Cybersecurity Risks: Potential breaches of security and unauthorized disclosure of information